克唑替尼治疗伴或不伴间变性淋巴瘤激酶基因改变的晚期不可手术炎性肌纤维母细胞瘤(欧洲癌症研究与治疗组织90101 CREATE):多中心、单药、前瞻性、非随机2期试验
这项多中心、生物标志物驱动、单药、非随机、开放标签、两阶段2期试验(EORTC 90101 CREATE)在8个欧洲国家13个研究站点纳入20例年龄≥15岁、局部诊断为晚期或转移性炎性肌纤维母细胞瘤且手术、放疗或全身治疗无法治愈的患者,口服克唑替尼250 mg每日两次持续给药。19例可评估主要终点,ALK阳性患者12例中6例(50%,95%CI 21.1-78.9)达到客观缓解,ALK阴性患者7例中1例(14%,95%CI 0.0-57.9)达到客观缓解。最常见治疗相关不良事件为恶心(11例[55%])、乏力(9例[45%])、视力模糊(9例[45%])、呕吐(7例[35%])和腹泻(7例[35%]);5例患者发生8起严重不良事件。作者认为克唑替尼达到预设成功标准,可考虑作为无法根治性手术的局部晚期或转移性ALK阳性炎性肌纤维母细胞瘤患者的标准治疗。
要点
- ALK阳性晚期不可手术炎性肌纤维母细胞瘤患者12例中6例(50%,95%CI 21.1-78.9)达到客观缓解,达到预设成功标准(≥6例缓解)。
- ALK阴性患者7例中仅1例(14%,95%CI 0.0-57.9)达到客观缓解,缓解率明显低于ALK阳性组。
- 给药方案为口服克唑替尼250 mg每日两次,持续每日给药,每周期21天,直至疾病进展、不可接受毒性或患者拒绝。
- 20例患者中最常见治疗相关不良事件为恶心(11例[55%])、乏力(9例[45%])、视力模糊(9例[45%])、呕吐(7例[35%])和腹泻(7例[35%])。
- 5例患者发生8起严重不良事件,包括肺炎、不明原因发热、心脏病发作伴肌酐升高及可能脓毒症、腹部脓肿伴急性肾功能不全和QT间期延长。
适用人群与场景
- 年龄至少15岁、局部诊断为晚期或转移性炎性肌纤维母细胞瘤且手术、放疗或全身治疗无法治愈的患者。
- 纳入条件包括可测量病灶、东部肿瘤协作组体能状态评分0-2分、血液学、肾功能和肝功能 adequate。
- ALK阳性或阴性由中心实验室基于存档肿瘤组织采用免疫组化和荧光原位杂交评估,定义为至少15%肿瘤细胞ALK免疫阳性或基因重排。
诊断标准与关键阈值
- ALK阳性定义为基于存档肿瘤组织、中心实验室免疫组化或荧光原位杂交显示至少15%肿瘤细胞ALK免疫阳性或重排。
- 客观缓解按RECIST 1.1标准由 local investigator 每两个周期确认一次,包括完全缓解或部分缓解。
- 预设成功标准:若前12例可评估ALK阳性患者中至少2例达到确认的完全或部分缓解则最多入组35例;若至少6例ALK阳性患者达到确认缓解则试验判定为成功。
处置流程与药物剂量
- 符合条件且ALK阳性或阴性的患者接受口服克唑替尼250 mg每日两次,持续每日给药,每治疗周期21天,直至记录到疾病进展、不可接受毒性或患者拒绝。
红旗征与不能漏的情况
- 5例患者发生8起严重不良事件:肺炎、不明原因发热、心脏病发作伴肌酐升高及可能脓毒症、腹部脓肿伴急性肾功能不全和QT间期延长。
研究设计与关键结果
- 多中心、生物标志物驱动、单药、非随机、开放标签、两阶段2期试验,在8个欧洲国家13个研究站点(5所大学医院和8家专科诊所)纳入并治疗20例可评估参与者,其中19例可评估主要终点。
- 中位随访863天(IQR 358-1304)。
- ALK阳性患者12例中6例(50%,95%CI 21.1-78.9)达到客观缓解;ALK阴性患者7例中1例(14%,95%CI 0.0-57.9)达到客观缓解。
- 20例参与者中最常见治疗相关不良事件为恶心(11例[55%])、乏力(9例[45%])、视力模糊(9例[45%])、呕吐(7例[35%])和腹泻(7例[35%])。
- 5例患者发生8起严重不良事件:肺炎、不明原因发热、心脏病发作伴肌酐升高及可能脓毒症、腹部脓肿伴急性肾功能不全和QT间期延长。
证据类型、等级与局限
- 证据类型:多中心、生物标志物驱动、单药、非随机、开放标签、两阶段2期试验(EORTC 90101 CREATE)。
- 作者结论:ALK阳性肿瘤患者中50%达到客观缓解,克唑替尼达到本试验预设成功标准;结果支持在炎性肌纤维母细胞瘤患者中抑制ALK的理论依据;作者认为克唑替尼可考虑作为无法根治性手术的局部晚期或转移性ALK阳性炎性肌纤维母细胞瘤患者的标准治疗。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于无法根治性手术的局部晚期或转移性ALK阳性炎性肌纤维母细胞瘤患者,作者认为克唑替尼可考虑作为标准治疗。
- ALK阴性患者中客观缓解率较低(7例中1例,14%),原文未据此给出ALK阴性患者的治疗推荐。
指南或共识出处
- European Organisation for Research and Treatment of Cancer 90101 CREATE试验,注册号ClinicalTrials.gov NCT01524926。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.
METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK). Eligible participants were patients aged at least 15 years with a local diagnosis of advanced or metastatic IMFT deemed incurable with surgery, radiotherapy, or systemic therapy; measurable disease; an Eastern Cooperative Oncology Group performance status of 0-2; and adequate haematological, renal, and liver function. Central reference pathology was done for confirmation of the diagnosis, and ALK positivity or negativity was assessed centrally using immunohistochemistry and fluorescence in-situ hybridisation based on archival tumour tissue and defined as ALK immunopositivity or rearrangements in at least 15% of tumour cells. Eligible ALK-positive and ALK-negative patients received oral crizotinib 250 mg twice per day administered on a continuous daily dosing schedule (the duration of each treatment cycle was 21 days) until documented disease progression, unacceptable toxicity, or patient refusal. If at least two of the first 12 eligible and assessable ALK-positive patients achieved a confirmed complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a maximum of 35 patients were to be enrolled. If at least six ALK-positive patients achieved a confirmed response, the trial would be deemed successful. The primary endpoint was the proportion of patients who achieved an objective response (ie, a complete or partial response) as per RECIST 1.1, with response confirmation assessed by the local investigator every other cycle. Activity and safety endpoints were analysed in the per-protocol population. This trial is registered with ClinicalTrials.gov, number NCT01524926.
FINDINGS: Between Oct 3, 2012, and April 12, 2017, we recruited and treated 20 eligible participants, 19 of whom were assessable for the primary endpoint. Median follow-up was 863 days (IQR 358-1304). Six of 12 ALK-positive patients (50%, 95% CI 21·1-78·9) and one of seven ALK-negative patients (14%, 0·0-57·9) achieved an objective response. The most common treatment-related adverse events in the 20 participants were nausea (11 [55%]), fatigue (9 [45%]), blurred vision (nine [45%]), vomiting (seven [35%]), and diarrhoea (seven [35%]). Eight serious adverse events occurred in five patients: pneumonia, fever of unknown cause, a heart attack with increased creatinine and possible sepsis, an abdominal abscess with acute renal insufficiency, and a QT prolongation.
INTERPRETATION: With 50% of participants with ALK-positive tumours achieving an objective response, crizotinib met the prespecified criteria for success in this trial. The results presented here support the rationale for inhibiting ALK in patients with IMFT. Crizotinib could be considered as the standard of care for patients with locally advanced or metastatic ALK-positive IMFT who do not qualify for curative surgery.
FUNDING: The European Organisation for Research and Treatment of Cancer and Pfizer.
参考来源
- Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018. PMID: 29669701. doi:10.1016/S2213-2600(18)30116-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。